Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 2/20 | 0.52 |
| ▸ | CYP11B2 | P19099 | 17/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 16/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2658682 | 0.84 | PTP4A3 (0.46) | TRPV4CYP11B2CYP11B1ALDH1A1 | |
| SCHEMBL10613739 | 0.83 | TRPV4 (0.55) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL10613747 | 0.83 | TRPV4 (0.55) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL22418175 | 0.82 | TRPV4 (0.46) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL28606434 | 0.82 | TRPV4 (0.53) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL16956451 | 0.81 | ALDH1A1 (0.43) | TRPV4ALDH1A1 | |
| SCHEMBL21872531 | 0.80 | ALDH1A1 (0.39) | TRPV4ALDH1A1 | |
| SCHEMBL29630883 | 0.80 | TRPV4 (0.52) | TRPV4CYP11B2CYP11B1ALDH1A1 | |
| SCHEMBL16953314 | 0.80 | TRPV4 (0.52) | TRPV4CYP11B2CYP11B1 | |
| SCHEMBL17954292 | 0.80 | TRPV4 (0.52) | TRPV4CYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4707920-A1 | NANOIMPRINT RESIST | Epinovatech AB (SE) | 2026-03-11 | — | — | EP | disclosed |
| US-12110294-B2 | CD73 compounds | GILEAD SCIENCES, INC. (US) | 2024-10-08 | — | — | US | disclosed |
| US-20240043427-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2024-02-08 | — | — | US | disclosed |
| WO-2023196601-A1 | OXADIAZOLE HDAC6 INHIBITORS AND USES THEREOF | EIKONIZO THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| EP-3632443-B1 | ANTI-TUMOR EFFECT POTENTIATOR USING A BIPHENYL COMPOUND | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-06-07 | — | — | EP | disclosed |
| EP-4143194-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2023-03-08 | — | — | EP | disclosed |
| US-20230039553-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| CN-115698009-A | CD73 inhibiting 2,4-dioxopyrimidine compounds | 吉利德科学公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-3381896-B1 | BIPHENYL COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO LTD (JP) | 2023-01-18 | — | — | EP | disclosed |
| WO-2021222522-A1 | CD73 INHIBITING 2,4-DIOXOPYRIMIDINE COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| CN-1656066-A | combination drug | ASTRAZENECA AB (SE) | 2005-08-17 | — | — | CN | disclosed |
| EP-1513807-A1 | PHARMACEUTICAL COMBINATION | AstraZeneca AB (SE) | 2005-03-16 | — | — | EP | disclosed |
| CN-1487919-A | Novel mandelic acid derivatives and their use as thrombin inhibitors | — | 2004-04-07 | — | — | CN | disclosed |
| US-20040019033-A1 | Mandelic acid derivatives and their use as throbin inhibitors | ASTRAZENECA AB (SE) | 2004-01-29 | — | — | US | disclosed |
| WO-2003101956-A1 | PHARMACEUTICAL COMBINATION | ASTRAZENECA AB (SE) | 2003-12-11 | — | — | WO | disclosed |
| EP-1347955-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | AstraZeneca AB (SE) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002044145-A1 | NEW MANDELIC ACID DERIVATIVES AND THEIR USE AS THROBIN INHIBITORS | ASTRAZENECA AB (SE) | 2002-06-06 | — | — | WO | disclosed |
| US-4784471-A | LIQUID CRYSTALS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1988-11-15 | — | — | US | disclosed |
| EP-0211876-A1 | FLUOROBENZENE DERIVATIVES | MERCK PATENT GmbH (DE) | 1987-03-04 | — | — | EP | disclosed |
| WO-1986004895-A1 | FLUOROBENZENE DERIVATIVES | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 1986-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039553-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | TRPV4 2125/4885CYP11B2 3903/4885CYP11B1 3902/4885 |
| US-20040019033-A1 | Mandelic acid derivatives and their use as throbin inhibitors | ADAMTS1, ADAMTS13, ADAMTS7 | TRPV4 3575/4885CYP11B2 1145/4885CYP11B1 404/4885 |
| US-20240043427-A1 | CD73 COMPOUNDS | ENTPD5, ENTPD1, NT5E | TRPV4 2125/4885CYP11B2 3903/4885CYP11B1 3902/4885 |
| US-12110294-B2 | CD73 compounds | ENTPD5, ENTPD1, NT5E | TRPV4 2737/4885CYP11B2 2855/4885CYP11B1 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.